Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Table salt

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Table salt. Displaying page 1 of 1.
    EudraCT Number: 2021-001329-29 Sponsor Protocol Number: TIG-006 Start Date*: 2021-07-15
    Sponsor Name:iTeos Belgium SA
    Full Title: A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors
    Medical condition: Advanced solid tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006088-23 Sponsor Protocol Number: MEK116513 Start Date*: 2012-06-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectab...
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) BE (Completed) AT (Completed) NO (Completed) IE (Completed) CZ (Completed) ES (Completed) NL (Completed) HU (Completed) FI (Completed) IT (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-004577-12 Sponsor Protocol Number: BRF116613 Start Date*: 2015-03-23
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: Phase II biomarker study evaluating the upfront combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib versus the combination after eight weeks of monotherapy with dabrafenib or tra...
    Medical condition: patients with metastatic and unresectable stage III or IV melanoma harbouring an activating BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012054-20 Sponsor Protocol Number: HZA106839 Start Date*: 2009-10-27
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Ad...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004868-35 Sponsor Protocol Number: AT-301 Start Date*: 2018-08-23
    Sponsor Name:Allecra Therapeutics SAS
    Full Title: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Cefepime- AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Ur...
    Medical condition: Complicated urinary tract infections including acute pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10037597 Pyelonephritis acute PT
    20.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) ES (Completed) BG (Completed) SK (Completed) PL (Completed) HU (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002431-15 Sponsor Protocol Number: CRFB002ADE23 Start Date*: 2013-10-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg ranibizumab PRN compared to 2 mg aflibercept bimonthly intravitreal injections on retinal thickness sta...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NO (Completed) AT (Completed) DK (Completed) BE (Completed) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006087-49 Sponsor Protocol Number: MEK115306 Start Date*: 2012-04-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subjec...
    Medical condition: Cutaneous melanoma - aggressive form of skin cancers.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040808 Skin cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) GB (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004875-21 Sponsor Protocol Number: BAY 43-9006 / 12913 Start Date*: 2008-01-21
    Sponsor Name:Bayer Healthcare AG, D-51368 Leverkusen, Germany
    Full Title: A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Rena...
    Medical condition: renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012983-14 Sponsor Protocol Number: DMS32212R Start Date*: 2009-10-21
    Sponsor Name:BioNumerik Pharmaceuticals, Inc.
    Full Title: Randomized, multicenter, double-blind, phase 3 trial of Tavocept versus Placebo in patients with newly diagnosed or relapsed advanced (stage IIIB/IV) primary adenocarcinoma of the lung treated with...
    Medical condition: Newly diagnosed or relapsed advanced (Stage IIIB/IV) primary adenocarcinoma of the lung
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025031 Lung adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001161-41 Sponsor Protocol Number: BRF113928 Start Date*: 2012-09-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-smal...
    Medical condition: Advanced non-small cell lung cancer and BRAF mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NO (Completed) DE (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002432-17 Sponsor Protocol Number: ALN-AS1-003 Start Date*: 2017-11-22
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: ENVISION: A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porph...
    Medical condition: Acute Hepatic Porphyrias (AHP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036182 Porphyria acute PT
    20.0 10010331 - Congenital, familial and genetic disorders 10036184 Porphyria hepatic LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) DK (Completed) CZ (Completed) SE (Completed) BG (Completed) FI (Completed) BE (Completed) FR (Completed) PL (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000280-16 Sponsor Protocol Number: CEMA401A2201 Start Date*: 2017-05-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients wi...
    Medical condition: Post-herpetic neuralgia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10036376 Post herpetic neuralgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) SK (Prematurely Ended) AT (Prematurely Ended) NO (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) FR (Completed) BE (Prematurely Ended) PT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019594-14 Sponsor Protocol Number: HZA106829 Start Date*: 2010-07-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, parallel group, multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder alone, and Fluticasone Propionate alone in th...
    Medical condition: Persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000681-55 Sponsor Protocol Number: 3475-022 Start Date*: 2015-10-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma
    Medical condition: advanced or metastatic melanoma - all parts of the trial advanced (unresectable and/or metastatic) solid tumours - Parts 4 and 5
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001447-39 Sponsor Protocol Number: AB15003 Start Date*: 2019-10-21
    Sponsor Name:AB SCIENCE
    Full Title: A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety ...
    Medical condition: Smouldering or Indolent Severe Systemic mastocytosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Prematurely Ended) PL (Trial now transitioned) RO (Ongoing) LT (Completed) NL (Temporarily Halted) IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 18:17:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA